Joan-Ramon Laporte Roselló (born in Barcelona in 1948) is a Spanish pharmacologist.
He is the son of Josep Laporte, a doctor and politician. He was born in Barcelona in 1948. He graduated from the University of Barcelona School of Medicine in 1970 and completed his doctorate there four years later.
Laporte served as a professor of pharmacology at the Autonomous University of Barcelona, the service director of the Department at the Hebron Valley University Hospital, and a partner of the World Health Organization in the field of drug evaluation.
As a pharmacovigilance expert, Laporte participated in the establishment of the pharmacology network of the Republic of Cuba and the European Pharmacovigilance Research Group of the European Commission in 1997. He was a candidate on the list of Catalan Green Party autonomous election initiative in 2010.
In 2004, Laporte won a trial against Merck Sharp & Dohme, an American pharmaceutical company, which sued him for warning of irregularities in clinical trials of the anti-inflammatory drug rofecoxib. Rofecoxib was recalled months after its launch due to cardiovascular risk.
In February 2022, in reaction to Laporte’s testimony before a Spanish parliamentary commission investigating the country’s vaccination effort, Laporte was accused by Spanish media of disinformation.